Skip to content
Vistide(cidofovir)
Vistide (cidofovir) is a small molecule pharmaceutical. Cidofovir was first approved as Vistide on 1996-06-26. It is used to treat aids-related opportunistic infections, cytomegalovirus infections, and cytomegalovirus retinitis in the USA. It has been approved in Europe to treat cytomegalovirus retinitis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
eye diseasesD005128
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cidofovir
Tradename
Company
Number
Date
Products
VISTIDEGilead SciencesN-020638 DISCN1996-06-26
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vistideNew Drug Application2013-09-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aids-related opportunistic infections—D017088—
cytomegalovirus infectionsEFO_0001062D003586B25
cytomegalovirus retinitisEFO_1001302D017726—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
— J05AB12: Cidofovir
HCPCS
Code
Description
J0740
Injection, cidofovir, 375 mg
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AsthmaD001249EFO_0000270J45—7256341
Allergic rhinitis perennialD012221EFO_1001417J30.89——142—16
Allergic rhinitisD065631J30.91—44—9
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitis seasonalD006255EFO_0003956J30—115——16
Covid-19D000086382U07.1—54——6
Severe acute respiratory syndrome-related coronavirusD045473NCBITaxon_227859—21——2
Respiratory tract diseasesD012140——1——1
Respiratory hypersensitivityD012130——1——1
PolypsD011127EFO_0000662——1——1
Sars-cov-2D000086402—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9—1———1
Viral pneumoniaD011024EFO_0007541J12.9—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypersensitivityD006967EFO_0003785T78.40————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCIDOFOVIR
INNcidofovir
Description
Cidofovir anhydrous is cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. It has a role as an antiviral drug, an antineoplastic agent, an anti-HIV agent and a photosensitizing agent. It is a pyrimidone and a member of phosphonic acids. It is a conjugate acid of a cidofovir(2-) and a cidofovir(1-).
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1
Identifiers
PDB—
CAS-ID113852-37-2
RxCUI1546007
ChEMBL IDCHEMBL152
ChEBI ID3696
PubChem CID60613
DrugBankDB00369
UNII ID768M1V522C (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,434 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vistide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,102 adverse events reported
View more details